16:56 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Merck's doravirine similar to ritonavir-boosted darunavir in Phase III for HIV-1 infection

Merck & Co. Inc. (NYSE:MRK) said once-daily oral doravirine (MK-1439) in combination with other antiretroviral therapies (ARTs) led to viral suppression at week 96 in 73.1% of patients vs. 66% of patients treated with ritonavir-boosted...
18:19 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS In vitro and cell culture studies identified an allophenylnorstatine-tetrahydrofuranylglycine conjugate-based inhibitor of HIV protease that could help treat protease inhibitor-resistant HIV infection. Chemical synthesis and in vitro activity assays of allophenylnorstatine-tetrahydrofuranylglycine conjugate analogs yielded...
02:09 , Feb 17, 2018 |  BioCentury  |  Politics, Policy & Law

FDA’s bigger piggy bank

FDA plans to use a proposed record-setting funding boost to invest in projects it believes could lead to fundamental improvements in the way medical products are tested, reviewed and manufactured. The goal is to use...
19:22 , Nov 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Cell culture studies identified a Prezista darunavir-based HIV protease inhibitor that could help treat protease inhibitor-resistant HIV/AIDS. Chemical synthesis and testing in human T cell-based viral replication assays of Prezista analogs yielded...
19:29 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

ViiV's Tivicay superior to Kaletra in Phase IIIb DAWNING trial for HIV-1 infection

In July, ViiV Healthcare Ltd. (Brentford, U.K.) said data from the Phase IIIb DAWNING trial to treat HIV-1 infection showed that a regimen containing Tivicay dolutegravir showed superior efficacy and had a favorable safety profile...
21:03 , Nov 2, 2017 |  BC Innovations  |  Translation in Brief

A new pocket for D4

The early promise of the dopamine D4 receptor as a therapeutic target for psychiatric disorders hasn’t been borne out because of the difficulty of producing sufficiently selective compounds. Last month in Science, a collaboration between...
21:31 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

China approves HCV drugs from Gilead and AbbVie

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir (GS-7977) to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older. Gilead said the nucleotide analog HCV...
21:54 , Sep 25, 2017 |  BC Extra  |  Company News

Gilead's Sovaldi gets Chinese approval

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older. Gilead said the nucleotide analog HCV NS5B...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five disease-associated...
18:56 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends expanded label for AbbVie’s Kaletra to treat HIV infection in infants

EMA’s CHMP recommended expanding the label for Kaletra lopinavir/ritonavir from AbbVie Inc. (NYSE:ABBV) to treat HIV-1 infection in children aged ≥14 days. Kaletra is currently approved in the EU to treat HIV-1 infection in patients...